Systemic Lupus Erythematosus (SLE) Clinical Trials

Find Systemic Lupus Erythematosus (SLE) Clinical Trials Near You

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study to Evaluate the Efficacy and Safety of SG301 SC Injection in Patients With Systemic Lupus Erythematosus

Status: Recruiting
Location: See all (40) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This was a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study. The primary objective was to evaluate the efficacy of SG301 SC injection in participants with Systemic Lupus Erythematosus (SLE) based on the Systemic Lupus Erythematosus Responder Index -4 (SRI-4) response rate. The secondary objectives were to assess the safety, pharmacokinetics, pharmacodynamics, and immunogenicity profiles of SG301 SC injection in these participants .

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:

• Voluntarily participate in the clinical study and sign a written informed consent form.

• Participants must be diagnosed with SLE in accordance with the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatism (ACR) SLE classification criteria and have inadequate response to standard treatment, intolerance to standard treatment, or recurrent disease.

• SLEDAI-2K score ≥ 8 points, with clinical features corresponding to a SLEDAI-2K score ≥ 4 points.

• Positive serological test results for autoantibodies, defined as antinuclear antibody (ANA) positivity and/or anti-double-stranded DNA (anti-dsDNA) antibody positivity.

• Body weight ≥ 35 kg.

• Must have received standard treatment for at least 8 weeks before the first dose and maintained a stable dose of the treatment unchanged for at least 4 weeks before the first dose.

• Participants of childbearing potential or whose partners are of childbearing potential must agree to use effective contraceptive measures throughout the entire study period and within 6 months after the last dose.

Locations
Other Locations
China
Peking University People's Hospital
RECRUITING
Beijing
Jilin Provincial People's Hospital
RECRUITING
Changchun
Jilin University First Hospital
RECRUITING
Changchun
Heping Hospital Affiliated to Changzhi Medical College
RECRUITING
Changzhi
Changzhou Second People's Hospital
RECRUITING
Changzhou
West China Hospital, Sichuan University
RECRUITING
Chengdu
The Second Affiliated Hospital of Chongqing Medical University
RECRUITING
Chongqing
Dalian Municipal Central Hospital
RECRUITING
Dalian
The First Affiliated Hospital of Gannan Medical University
RECRUITING
Ganzhou
ZhuJiang Hospital of Southern Medical University
RECRUITING
Guangzhou
The First Affiliated Hospital of Guilin Medical University
RECRUITING
Guilin
The 2nd Affiliated Hospital of Harbin Medical University
NOT_YET_RECRUITING
Harbin
Huzhou Third People's Hospital
RECRUITING
Huzhou
JingZhou Central Hospital
RECRUITING
Jingzhou
Jining First People's Hospital
RECRUITING
Jining
The First People's Hospital of Yunnan Prevince
RECRUITING
Kunming
Hebei Zhongyuan Petrolium Central Hospital
RECRUITING
Langfang
GanSu Provincial Hospital
RECRUITING
Lanzhou
The First Hospital of Lanzhou University
RECRUITING
Lanzhou
Linfen Central Hospital
RECRUITING
Linfen
Luoyang Central Hospital
RECRUITING
Luoyang
The First Affiliated Hospital of Henan University of Science and Technology
RECRUITING
Luoyang
The First Affiliated Hospital of Guangxi Medical University
RECRUITING
Nanning
Pingxiang People's Hospital
RECRUITING
Pingxiang
Shenzhen People's Hospital
RECRUITING
Shenzhen
Hebei General Hospital
RECRUITING
Shijiazhuang
Shiyan People's Hospital
RECRUITING
Shiyan
The Second Affiliated Hospital of Soochow University
RECRUITING
Suzhou
Second Hospital of Shanxi Medical University
RECRUITING
Taiyuan
Shanxi Bethune Hospital
RECRUITING
Taiyuan
Tianjin Medical University General Hospital
RECRUITING
Tianjin
The First Affiliated Hospital of Wenzhou Medical University
RECRUITING
Wenzhou
The Central Hospital of Wuhan
RECRUITING
Wuhan
Xiamen Hospital of Traditional Chinese Medicine
RECRUITING
Xiamen
Xiamen University Affiliated Zhongshan Hospital
RECRUITING
Xiamen
Northern Jiangsu People's Hospital
RECRUITING
Yangzhou
Yichang Central People's Hospital
RECRUITING
Yichang
Yichun People's Hospital
RECRUITING
Yichun
People's Hospital of Zhengzhou
RECRUITING
Zhengzhou
Zhuzhou Central Hospital
RECRUITING
Zhuzhou
Contact Information
Primary
Yue Song
songyue@sumgenbio.com
+86-18511021346
Time Frame
Start Date: 2026-03-26
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 120
Treatments
Experimental: SG301 SC - A
SG301 SC Injection
Experimental: SG301 SC -B
SG301 SC Injection
Placebo_comparator: Placebo
SG301 SC Placebo
Related Therapeutic Areas
Sponsors
Leads: Hangzhou Sumgen Biotech Co., Ltd.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials